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 1 
ABSTRACT 30 
Individuals with type 2 diabetes mellitus (T2DM) have a greater blood pressure (BP) response to 31 
acute maximal exercise compared to those without T2DM; however, whether they exhibit a 32 
different arterial stiffness (AS) response to maximal exercise has yet to be explored. Adults with 33 
(n=66) and without T2DM (n=61) underwent an ‘arterial stress test’: at rest and immediately 34 
post-exercise, carotid-femoral pulse wave velocity (cfPWV), the gold-standard measure of AS, 35 
brachial BP, heart rate (HR) and other hemodynamic measurements were assessed. Linear 36 
regression models were used to evaluate between-group differences at rest, and the response to 37 
exercise (post-exercise value), adjusting for covariates including BP and HR when relevant, and 38 
the corresponding baseline value of each parameter. All participants (mean±SD: age 59.3±10.6 39 
years; BMI 31.2±3.9 kg/m2) had hypertension (mean BP 130±14/80±9 mmHg). At rest, 40 
participants with T2DM had significantly higher cfPWV (10.3±2.7 vs. 9.1±1.9 m/s), HR (69±11 41 
vs. 66±10 beats/min), and lower DBP (79±9 vs. 83±9 mmHg), but SBP (129±15 vs. 131±13 42 
mmHg) was similar. In response to exercise, participants with T2DM showed greater increases 43 
in cfPWV (1.6, 95%CI 0.4, 2.9 m/s), and SBP (9, 95% CI 1, 17 mmHg) than participants without 44 
T2DM. A greater proportion of participants with T2DM had a hypertensive response to exercise 45 
compared to participants without T2DM (n=23, 35% vs. n=11, 18%) (P=0.033). By 46 
incorporating exercise as a vascular stressor, we provide evidence of a greater increase in AS in 47 
individuals with T2DM, independently of resting AS, and the BP post-exercise.  48 
 49 
Keywords: arterial stiffness, hypertension, type 2 diabetes mellitus, exercise, blood pressure, 50 
exercise testing  51 
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INTRODUCTION 52 
       Type 2 diabetes mellitus (T2DM) increases arterial stiffness through pathological changes in 53 
the vasculature, including reduced nitric oxide bioavailability, increased oxidative stress and 54 
inflammation, as well as structural changes within the arterial wall1. As a result, for many 55 
individuals with T2DM, their vascular “age” surpasses their chronological age2. Furthermore, 56 
during maximal exercise, individuals with T2DM are more likely to experience an exaggerated 57 
blood pressure (BP) response3; this is defined as a rise in systolic BP (SBP) exceeding 210 58 
mmHg in men and 190 mmHg in women, and is associated with higher cardiovascular disease 59 
(CVD) risk and mortality4. The physiological changes underlying this altered response have not 60 
been fully elucidated, but underlying vascular abnormalities are thought to play a pivotal role5. 61 
However, whether individuals with T2DM have a different arterial stiffness response to exercise, 62 
independent of the resting value, has yet to be explored. In this context, increased demands 63 
associated with acute exercise might exaggerate vascular abnormalities present in these 64 
individuals.  65 
      The ‘gold standard’ metric for assessing arterial stiffness non-invasively is carotid-femoral 66 
pulse wave velocity (cfPWV), a measure of the speed of the pressure pulse wave in the central 67 
elastic arteries6. Higher values of cfPWV indicate greater arterial stiffness, which is associated 68 
with a greater risk of CVD events and mortality7, 8.  69 
      With increased metabolic demands during acute exercise, the vascular system plays an 70 
important role in the redistribution of blood flow to ensure adequate perfusion of the exercising 71 
muscle9. This leads to a transient increase in mean arterial pressure, sympathetic activity, and 72 
vascular tone, as well as central arterial stiffness9. During the recovery period, arterial stiffness 73 
has been shown to decrease to a level at, or below resting values9. While the initial increase in 74 
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arterial stiffness is recognized as a normal adaptation to acute exercise, the extent of the increase 75 
in arterial stiffness and recovery trajectory may reflect the ability of the arteries to respond to 76 
increased demands. 77 
      In the present study, we aimed to examine the acute response of arterial stiffness and 78 
hemodynamic parameters to maximal exercise in adults with and without T2DM. We 79 
hypothesized that individuals with T2DM would have a higher arterial stiffness in response to 80 
exercise, independently of the resting values and BP.   81 
 4 
METHODS 82 
     The data that support the findings of this study are available from the corresponding author 83 
upon reasonable request.  84 
Ethical Approval 85 
      The study was approved by the ethics review board of McGill University Faculty of 86 
Medicine. Written informed consent was obtained from all participants.  87 
Study Cohort 88 
      Participants were recruited through McGill-affiliated clinics for the SMARTER trial, a one-89 
year randomized controlled trial examining the impact of step count prescriptions on arterial 90 
health10. All participants of the trial were overweight or obese (body mass index 25-40 kg/m2), 91 
had T2DM and/or hypertension, and did not have any gait abnormalities preventing exercise. 92 
Hypertension and T2DM were diagnosed by the referring physician following Canadian 93 
guidelines11, 12. The analyses herein were conducted in hypertensive participants with and 94 
without T2DM who underwent the ‘arterial stress test’ at the baseline evaluation.  95 
Exercise Testing 96 
      All participants underwent a maximal exercise test to exhaustion on a treadmill following a 97 
modified Bruce protocol13. Peak oxygen consumption (VO2 peak) was obtained using a metabolic 98 
cart (Medisoft’s Ergocard, Sorinne, Belgium). To ensure all participants had achieved 99 
exhaustion, participants who did not attain age-based cutoffs for the respiratory exchange ratio 100 
(RER) were excluded (aged 20-49: RER≥1.10; aged 50-64: RER≥1.05; aged ≥65: RER≥1.00)14. 101 
Peak heart rate (HR) was obtained using the 3-lead electrocardiogram (ECG) connected to the 102 
metabolic cart but was not used as a criterion to establish maximal effort due to the influence of 103 
β-blockers on the HR response to exercise.  104 
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Arterial Stiffness and Hemodynamics 105 
      All measurements were performed in the morning to avoid circadian rhythm variations15, 16.  106 
Participants fasted for 12 hours prior to the assessment, and abstained from caffeine, alcohol, and 107 
smoking. Participants were offered a small healthy snack after the blood draw and prior to the 108 
‘arterial stress test’ to prevent hypoglycemia and because a fasted state could have prevented 109 
participants from exerting themselves fully. Participants avoided exercise for 24 hours prior to 110 
the assessment. All usual medications, except anti-hyperglycemic agents, were taken the 111 
morning of assessment.  112 
        Brachial BP was measured using an automated oscillometric BP monitor (BpTRU, Medical 113 
Devices Ltd, BC, Canada) in a seated position at rest12, as well as in a supine position at rest and 114 
after exercise (at 3, 5, 10, 15 and 20 minutes), following the cfPWV measurement. MAP was 115 
calculated as: brachial diastolic BP (DBP) + 1/3(brachial SBP-DBP)17. Due to the impact of 116 
body position on BP, brachial BP was assessed in the supine position in order to calibrate the 117 
central hemodynamic measures obtained in a supine position. Standing measurements of brachial 118 
BP were obtained manually using the auscultatory method immediately before and after exercise 119 
(0 minutes). This measure was used to evaluate whether participants experienced a hypertensive 120 
response to exercise, which was defined as a brachial SBP >210 mmHg in men and >190 mmHg 121 
in women4. 122 
      Arterial stiffness, central BP, and augmentation index (AIx) were measured using 123 
applanation tonometry (SphygmoCor, AtCor Medical, Sydney, Australia) in a supine position 124 
before and immediately after exercise following a standardized protocol in a controlled 125 
environment at the Vascular Health Unit at the McGill University Health Centre. Baseline 126 
measurements were obtained after a 10-minute rest period. Following exercise completion, 127 
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participants returned to a supine position for the measurement of cfPWV (at 3, 5, 10, 15, and 20 128 
minutes) and carotid-radial PWV (crPWV), central BP and AIx (at 5, 10, 15, and 20 minutes). 129 
As per SphygmoCor recommendations, the radial pressure waveforms were calibrated using 130 
brachial SBP and DBP. As calibration with MAP and DBP has been increasingly suggested18, we 131 
also performed this analysis. HR was acquired at the same time as the cfPWV measurement 132 
using the built-in 3-lead ECG. To account for the influence of HR on wave reflection, AIx was 133 
corrected for a HR of 75 beats/ minute (AIx75). Path length was estimated using the subtraction 134 
method, whereby the distance between the carotid artery site and the sternal notch was subtracted 135 
from the distance between the sternal notch and the femoral artery site6. At rest, measurements 136 
were repeated until two PWV measurements were within 0.5 m/s, and two augmentation 137 
pressures were within 4%. PWA measurements with an operator index <80 and PWV 138 
measurements with a pulse transit time standard deviation >13% or HR difference >5 beats/min 139 
between sites were deemed poor quality and not considered. Due to time restrictions post-140 
exercise, only one good quality measurement was collected. Non-invasively recorded central 141 
waveforms (derived from the radial artery) have been validated against invasively recorded 142 
central waveforms at rest, as well as during and after cycling exercise19. Furthermore, good test-143 
retest reproducibility has been demonstrated for cfPWV, central BP and AIx acquired during and 144 
after exercise20, 21. 145 
     We also evaluated the BP-independent changes in arterial stiffness by calculating an index of 146 
stiffness that is considered equivalent to the intrinsic stiffness index β0, where β0 is the exponent 147 
of the pressure (P)-diameter (D) relationship within the vessel22: 148 





 . 149 
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Pref is a reference pressure and Dref is the diameter of the artery at the reference pressure. Using 150 
cfPWV, the corresponding brachial DBP (Pd), and estimated blood mass density (ρ=1.050 kg/L), 151 
and Pref=100 mmHg, aortic stiffness index β0 was determined







) . 153 
      The left ventricular ejection duration was derived from the central pressure waveform and 154 
calculated as the time from the foot of the waveform to the incisura.  155 
     The timing of the measurements is summarized in Figure 1. Due to a short time window post-156 
exercise, we prioritized the measurement of brachial BP and cfPWV at the 3-minute time point. 157 
From 5 minutes onwards, all parameters were measured, in the same order for all participants.  158 
Blood Collection 159 
      Fasting venous blood samples were obtained for the quantification of glucose and insulin 160 
levels following standard laboratory methods. In participants not taking insulin, fasting glucose 161 
and insulin values were used to compute the Homeostatic Model Assessment-Insulin Resistance 162 
(HOMA-IR).  163 
Analysis 164 
     Demographic factors and resting parameters were compared between groups using the 165 
Student’s T-test or Mann-Whitney test, as appropriate. Categorical variables were assessed using 166 
the chi-square test for independence. Linear regression models were used to evaluate between-167 
group differences in hemodynamic parameters post-exercise. In evaluating the response to 168 
exercise, models were consistently adjusted for the baseline parameter, age, sex, as well as 169 
waist:hip ratio and angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor 170 
blocker (ARB) use to account for group differences in these variables. ACEis/ARBs are known 171 
to influence the cardiovascular response to exercise. We further evaluated models with and 172 
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without statin use due to group differences, but it should be noted that statin use was strongly 173 
correlated with T2DM status, given that clinical guidelines recommend statin therapy in patients 174 
with T2DM. Further, all measurements were adjusted for HR at the time of measurement.  175 
      To correct for the BP dependence of cfPWV, brachial DBP at the time of the measure was 176 
included as a covariate in our statistical models. DBP was chosen given that the SphygmoCor 177 
system uses the diastolic foot of the proximal and distal waveforms for the estimation of transit 178 
time, and therefore, provides a velocity measure that is dependent on DBP. However, we also 179 
assessed differences adjusting for mean arterial pressure (MAP) since we acknowledge that the 180 
brachial BP differs from central BP, and this difference may be amplified during exercise24. 181 
Lastly, we also evaluated two separate models, where 1) both SBP and DBP were included, and  182 
2) SBP replaced DBP.   183 
     To evaluate the impact of T2DM on overall vascular function after physical stress, area under 184 
the curve (AUC) values were calculated for vessel hemodynamic parameters measured at 185 
baseline, 3, 5, 10, 15, and 20 minutes. In order to compare the AUC irrespective of the baseline 186 
value, a ‘baseline AUC’ was determined using the pre-exercise value and subtracted from the 187 
total AUC (Figure S1). Differences in the AUC were assessed using linear regression, adjusting 188 
for age, sex, waist:hip ratio, and ACEi/ARB use.  189 
     Mean differences between groups were computed with 95% confidence intervals (CIs). SAS 190 
V9.3 was used.   191 
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RESULTS 192 
     Overall, 266 participants completed the exercise test. We excluded 1) participants with T2DM 193 
who did not have hypertension (n=30), 2) participants who did not meet criteria for exhaustion 194 
(n=80), and 3) participants who were missing the 3-minute post-exercise arterial stiffness 195 
measures (n=26) (Figure 2). We further identified two participants with T2DM who were 196 
significant outliers when we evaluated the post-exercise cfPWV, and whose inclusion likely 197 
exaggerated between-group differences (Table S1). Excluded participants who did not reach 198 
exhaustion during the exercise test exercised for a shorter duration, and had a lower VO2peak and 199 
peak HR, but were otherwise comparable to those who were included in the final analysis (Table 200 
S2). Our main analyses compared participants with (n=66) and without T2DM (n=61).  201 
     In our main analysis, participants with T2DM had a greater waist:hip ratio, but body mass 202 
index was similar. A comparable proportion of participants with and without T2DM were treated 203 
for hypertension; however, a greater proportion with T2DM were taking ACEi/ARBs, in 204 
accordance with clinical practice guidelines (Table 1)12. There were differences in the lipid 205 
profile, and statins were taken by 79% of participants with T2DM versus 33% without T2DM. 206 
Fasting glucose and HOMA-IR levels were higher in those with T2DM, who had a mean 207 
hemoglobin A1c of 7.9±1.3%. 208 
     At rest, participants with T2DM had higher cfPWV and aortic stiffness β0, and lower central 209 
and brachial DBP, but no significant differences in SBP or other hemodynamic measures were 210 
noted (Table 1). 211 
Response to Exercise  212 
     Unadjusted values of all parameters post-exercise are presented in the online supplement 213 
(Table S3). In adjusted analyses, no differences were observed between subjects with and 214 
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without T2DM for the duration of exercise, exercise capacity (VO2peak), or maximal HR (Table 215 
2). A higher proportion of participants with T2DM had a hypertensive response to exercise 216 
compared to participants without T2DM [n=23 (35%) vs. n=11 (18%); difference 17% (95% CI 217 
2, 32 %)]. However, the peak exercise BP (0 minutes) was not significantly different between 218 
groups in adjusted analyses. Table 2 also presents the arterial stiffness and hemodynamic 219 
parameters according to their first available measurement post-exercise (3 or 5 minutes) to 220 
demonstrate the initial response to exercise. Immediately after exercise (at 3 minutes), we 221 
observed significantly greater brachial SBP by 8.9 mmHg (95% CI 0.9, 16.9 mmHg) in 222 
participants with T2DM, but no differences in DBP or peak HR. 223 
     Interestingly, participants with T2DM had a greater increase in cfPWV and aortic stiffness β0, 224 
as well as pulse pressure. The differences in cfPWV persisted in models adjusting for brachial 225 
DBP at the time of measurement (Table 2), MAP, and both SBP and DBP (Table S4). The 226 
increase in cfPWV was not significant when adjusting for only brachial SBP post-exercise 227 
(Table S4). In addition, it is noteworthy that the elevated SBP at 3 minutes post-exercise in 228 
T2DM was no longer significant when additionally adjusting for the corresponding post-exercise 229 
cfPWV [6.1 (95% CI -2.1, 14.2 mmHg)]. A significant between-group difference in aortic 230 
stiffness β0 remained when SBP was included (7.70, 95% CI 0.05, 15.34). Univariate, partially 231 
adjusted, and fully adjusted models for aortic stiffness β0 are presented in Table S5.  232 
      No significant differences in central BP, crPWV, AIx75, or left ventricular ejection duration 233 
were observed. Calibration of central BP with brachial MAP and DBP instead of SBP and DBP 234 
did not change the results (Table S6).  235 
      Participants with T2DM exhibited a greater AUC for cfPWV, aortic stiffness β0, and brachial 236 
SBP and DBP than participants without T2DM (Table 3). There were no differences between 237 
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subjects with and without T2DM beyond 3 minutes for brachial SBP (Figure 3). While the 238 
overall AUC was different between groups for brachial DBP, there were no differences at 3 239 
minutes, or at other points during the recovery. cfPWV and aortic stiffness β0 were both 240 
significantly different at 3, 5, 10 and 20 minutes in unadjusted analyses, and only at 3 and 10 241 
minutes in adjusted analyses, accounting for the pre-exercise value, age, sex, waist:hip ratio, 242 
ACEi/ARB use, and DBP (cfPWV only) and HR at the time of measurement. Between-group 243 
differences for all parameters during recovery (5, 10, 15 and 20 minutes) are presented in Table 244 
S7.   245 
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DISCUSSION 246 
     By incorporating exercise as a vascular stressor, we provide evidence of a greater increase in 247 
cfPWV and aortic stiffness β0 in individuals with T2DM, independently of resting arterial 248 
stiffness, and the brachial BP post-exercise. In a fully adjusted model, we observed a difference 249 
in cfPWV of 1.6 m/s between individuals with and without T2DM. A meta-analysis of 17 250 
longitudinal studies (n=15,877 individuals) showed that a 1 m/s increase in resting aortic 251 
stiffness corresponds to a 14%, 15%, and 15% increased risk of CVD events, CVD mortality and 252 
all-cause mortality, respectively, adjusting for traditional CVD risk factors7. This robust 253 
association was confirmed in a more recent large individual participant meta-analysis in 17,635 254 
individuals8. While the clinical significance of differences in cfPWV post-exercise has not been 255 
established, the magnitude of the difference in cfPWV observed in our study is not trivial.   256 
     Calculating the AUC allowed us to generate a single variable that summarizes multiple 257 
longitudinal measurements, capturing the combined response and recovery of each parameter to 258 
maximal stress. Our results, indicating significant differences in the AUC for cfPWV and aortic 259 
stiffness β0, support an overall difference in the response of arterial stiffness to exercise between 260 
individuals with and without T2DM. The AUC for brachial SBP was also higher in individuals 261 
with T2DM but this was mainly driven by differences between groups immediately post-262 
exercise, given that both groups followed a similar trajectory afterwards, i.e., from 5 to 20 263 
minutes post-exercise.  264 
     In subjects with T2DM, we observed a greater increase in brachial SBP at 3 minutes post-265 
exercise, which is in line with findings by Scott and colleagues demonstrating an excessive rise 266 
in brachial SBP in response to maximal treadmill exercise in adults with T2DM compared to 267 
healthy controls3. While they also observed a significantly greater increase in central SBP 268 
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immediately post-exercise (<3 minutes), we only observed a trend for an increase, likely because 269 
central BP in our study was captured 5 minutes post-exercise, at which point values had returned 270 
to baseline.   271 
       To our knowledge, no prior studies have evaluated the arterial stiffness response 272 
immediately post-maximal exercise in adults with T2DM. A study of a hypertensive population 273 
demonstrated elevated cfPWV 40 minutes and 1 hour after maximal cycling exercise compared 274 
with baseline levels25. This increase post-exercise was not observed in normotensive controls; 275 
however, this analysis did not compare the post-exercise cfPWV between groups. Instead, we 276 
have demonstrated an elevated cfPWV response in individuals with T2DM and hypertension 277 
compared to subjects with hypertension alone. Climie and colleagues compared the arterial 278 
stiffness and hemodynamic response to a short bout of light-moderate cycling exercise between 279 
individuals with T2DM and healthy controls26. They measured cfPWV while still on the cycle 280 
ergometer, enabling more immediate cfPWV measurements. They observed a significantly 281 
higher cfPWV post-exercise in individuals with T2DM (unadjusted); however, this analysis did 282 
not account for differences in resting cfPWV or other covariates, as this was not the main interest 283 
of this paper.  284 
     The relationship between arterial stiffness and BP is bi-directional and complex27. Arterial 285 
stiffening increases the amplitude of the forward traveling pressure waves, as well as the speed 286 
of propagation of both the forward and backward waves6. Consequently, the reflected waves 287 
return earlier during the cardiac cycle and become superimposed on the systolic part of the 288 
forward wave, leading to elevated central SBP and a widened pulse pressure6. Interestingly, 289 
during light-moderate cycling exercise, the elevation in central SBP is mainly due to an increase 290 
in the amplitude of the forward travelling wave, rather than reflected waves28. Therefore, arterial 291 
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stiffness and forward wave amplitude both contribute to the BP change observed during exercise. 292 
Conversely, given the exponential relationship between artery diameter and pressure, there is a 293 
clear acute relationship between the arterial BP and stiffness, represented by the tangent slope23. 294 
Therefore, the intrinsic stiffness of the artery will depend on BP. This bi-directional relationship 295 
complicates the assessment of arterial stiffness independently of BP; however, different 296 
mechanisms for evaluating the BP-independent response of arterial stiffness have been 297 
proposed23. Most commonly, arterial stiffness is statistically adjusted for BP at the time of 298 
measurement. Adjusting for the MAP is often recommended6; however, adjusting for the DBP 299 
may be more relevant as this represents the pressure in the artery when the transit time is 300 
calculated29. We have performed analyses adjusting for brachial DBP as well as for MAP. 301 
Hermeling and colleagues have demonstrated that PWV changes dramatically over the cardiac 302 
cycle, reporting a mean difference of 2.4 m/s between the diastolic and systolic phase (range 0.8-303 
4.4 m/s)30. In our study we have calculated transit time using the foot of the arterial pressure 304 
waveform, and therefore, elected to adjust analyses for the brachial DBP. Similarly, aortic 305 
stiffness β0 is derived by inputting the DBP. Spronck and colleagues demonstrated that cardio-306 
ankle vascular index (CAVI), which has been proposed to be a pressure-independent estimate of 307 
the intrinsic stiffness β, may show a residual acute BP dependence23. They provide a modified 308 
formula that theoretically removes the acute BP dependence, yielding CAVI0. Our inclusion of 309 
cfPWV versus heart-to-ankle PWV in the case of CAVI0 provides an estimate of the intrinsic 310 
stiffness β0 in the central elastic arteries. In our study, statistical correction of cfPWV for DBP, 311 
and the aortic stiffness β0 yielded comparable results. Similar to cfPWV, a significant aortic 312 
stiffness β0 difference remained when adjusting for SBP. This observation strengthens our 313 
finding that the observed difference in arterial stiffness between groups is independent of the 314 
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intrinsic arterial stiffness dependence on DBP (as corrected for through calculation of aortic 315 
stiffness β0), as well as independently of SBP. We also observed an elevated cfPWV response in 316 
models adjusting for MAP. A significant association between brachial SBP immediately post-317 
exercise and the corresponding post-exercise cfPWV was also noted. Specifically, the elevated 318 
SBP response post-exercise in T2DM was no longer significant when adjusting for the 319 
corresponding post-exercise cfPWV. On the other hand, the higher cfPWV response in T2DM 320 
was independent of brachial SBP and DBP post-exercise. Taken together, these findings indicate 321 
that arterial stiffness may mediate the exaggerated SBP increase. 322 
     Participants with T2DM had elevated arterial stiffness at rest, which is likely a function of 323 
structural changes of the arteries. High levels of circulating glucose lead to the development of 324 
advanced glycation end products, whereby glucose forms cross-links with collagen proteins 325 
within the arteries, and therefore, may alter the important balance between elastin and collagen1. 326 
Hyperglycemia causes the activation of protein kinase C, which leads to the generation of 327 
reactive oxygen species, and inflammation, further altering the structural and functional integrity 328 
of vascular wall1. When assessing post-exercise values of cfPWV, we have adjusted for resting 329 
values of cfPWV. Furthermore, we have demonstrated that the increase in arterial stiffness after 330 
acute exercise occurs independently of BP at the time of measurement, suggesting that these 331 
changes are due to changes in intrinsic properties of the arterial wall. As structural changes in 332 
such time frame (minutes) are unlikely, we attribute differences in response to exercise mainly to 333 
functional changes. For example, individuals with T2DM have endothelial dysfunction; higher 334 
levels of endothelin-1 and reduced nitric oxide bioavailability may cause an impaired 335 
vasodilatory response and increased arterial stiffness post-exercise1. Additionally, excess 336 
sympathetic activity in individuals with T2DM may potentiate greater exercise-induced 337 
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vasoconstriction1. It is noteworthy that vasoconstriction does not always lead to a functional 338 
increase in stiffness; for example, in healthy subjects, vasoconstriction may shift pressure load 339 
bearing towards elastin, offloading the stiff collagen. However, in individuals with T2DM who 340 
have impaired arterial function, vasoconstriction presumably leads to increased functional 341 
stiffness31.  342 
      The sample size of our study is relatively small; however, we demonstrated conclusive 343 
between-group differences in our main outcome, while adjusting for relevant covariates. This 344 
study constituted a secondary analysis of our SMARTER trial10, and thus we did not carry out 345 
power calculations a priori. Due to time constraints post-exercise, we could only obtain single 346 
measurements at each time point and were only able to measure select indices of arterial stiffness 347 
(i.e., cfPWV) at the 3-minute time point. Thus, we were not able to capture differences in central 348 
hemodynamic parameters earlier, as these measurements were only obtained after 5 minutes 349 
post-exercise. To this end, because we did not have central DBP measures immediately after 350 
exercise wwe have included brachial DBP in our models. However, DBP is relatively stable, 351 
with little difference between peripheral and central values6. Pulse pressure amplification 352 
increases during exercise in healthy individuals24; however, a follow-up study by the same group 353 
demonstrated that the degree of amplification is reduced in older patients with 354 
hypercholesterolemia32. Moreover, the pulse pressure amplification is likely driven more by an 355 
increase in SBP. We examined central and peripheral BP at 5 minutes; although on average 356 
brachial SBP was 15 mmHg greater than central SBP, there was only a 2 mmHg average 357 
difference for DBP (data not shown). Therefore, while brachial DBP seems to closely estimate 358 
the central DBP, we still included analyses adjusting for MAP (mainly driven by DBP)17. 359 
Following guidelines, measurements of arterial stiffness and hemodynamics were performed in a 360 
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supine position pre- and post-exercise; however, we were not able to control for the possible 361 
postural influence of lying down after treadmill exercise on vessel hemodynamics. Since we 362 
aimed to provoke maximal changes in arterial stiffness and hemodynamics, a graded treadmill 363 
test was selected over supine cycling exercise. Lastly, since all participants included in our 364 
analysis were hypertensive, the results of this study may not be generalizable to younger, lower-365 
risk individuals with T2DM.  366 
 367 
PERSPECTIVES 368 
      Our study has demonstrated that evaluating the exercise-induced response of arterial stiffness 369 
provides additional information by capturing the effect of T2DM on the ability of the arteries to 370 
respond to increased demands during exercise. Central arterial stiffness directly influences BP 371 
and likely contributes to the exaggerated BP response in participants with T2DM. Increased 372 
central arterial stiffness has a number of clinical consequences; it imposes a greater load on the 373 
left ventricle, decreases coronary perfusion, and exposes the microcirculation and end-organs to 374 
increased pulsatile pressure. Given that we do not spend our lives at rest, and physical stress 375 
commonly occurs during daily activities, this altered arterial stiffness response to strenuous 376 
exercise may contribute to the increased risk for CVD events in these individuals. The ‘arterial 377 
stress test’ may serve as a useful model for evaluating vascular impairment and CVD risk in 378 
individuals with T2DM. Future studies are needed to confirm the clinical utility of this model.  379 
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NOVELTY AND SIGNIFICANCE 494 
What is new? 495 
• Our study is the first to examine the acute response of arterial stiffness and hemodynamic 496 
parameters to acute maximal exercise in individuals with hypertension and with and 497 
without type 2 diabetes mellitus (T2DM) 498 
• We provide evidence of a greater increase in carotid-femoral pulse wave velocity, the 499 
‘gold standard’ measure of central arterial stiffness, in individuals with T2DM in 500 
response to acute maximal exercise, independently of resting arterial stiffness and the 501 
blood pressure (BP) post-exercise 502 
• A significantly higher post-exercise response of aortic stiffness β0,  a novel BP 503 
independent measure of arterial stiffness, was observed in individuals with T2DM versus 504 
without T2DM 505 
What is relevant? 506 
• Our study confirmed an exaggerated BP response in individuals with T2DM, which has 507 
been previously associated with higher cardiovascular disease risk and mortality 508 
• Our findings demonstrating a greater arterial stiffness response in individuals with T2DM 509 
help unravel the physiological mechanisms of the elevated BP response to exercise 510 
observed in this population 511 
Summary 512 
• By incorporating acute maximal exercise as a vascular stressor, we provide evidence of a 513 
greater increase in arterial stiffness post-exercise in individuals with hypertension and 514 
T2DM compared to individuals with hypertension alone  515 
 25 
FIGURE LEGENDS 516 
 517 
Figure 1. Timing of procedures included in the ‘arterial stress test’ protocol.  518 
AIx75, augmentation index corrected for a HR of 75 beats/minute; BP, blood pressure; cfPWV, 519 
carotid-femoral pulse wave velocity; crPWV, carotid-radial pulse wave velocity; HR, heart rate; 520 
RER, respiratory exchange ratio, VO2, oxygen consumption.  521 
 522 
Figure 2. Participant flowchart outlining the number of participants excluded from the final 523 
analysis.  524 
cfPWV, carotid-femoral pulse wave velocity; RER, respiratory exchange ratio; T2DM, type 2 525 
diabetes mellitus.  526 
 527 
Figure 3. Trajectory of unadjusted A) cfPWV, B) aortic stiffness β0, C) systolic blood pressure 528 
and D) diastolic blood pressure changes from rest to post-exercise at 3, 5, 10, 15, and 20 minutes. 529 
Error bars represent 95% confidence intervals. Linear regression models were used. *Indicates a 530 
significant between-group difference in unadjusted analyses, and ^ indicates a significant 531 
difference in adjusted analyses (described in Table 2). 532 
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TABLES 539 
Table 1: Baseline characteristics 540 





Demographic factors    
Age (years) 59.0±10.4 59.6±10.9 0.749 
Women, no (%) 35 (57.4) 28 (42.4) 0.092 
Body mass index (kg/m2) 31.7±3.9 30.7±3.8 0.132 
Waist circumference (cm) 101.7±9.5 103.4±10.1 0.353 
Hip circumference (cm) 111.8±8.9 107.2±7.7 0.002 
Waist:hip ratio  0.91±0.07 0.96±0.07 <0.001 
Smoking history, no (%)    
Past Smoker 21 (34.4) 23 (35.4) 0.910 
Current Smoker 2 (3.3) 5 (7.6) 0.269 
Type 2 Diabetes     
Duration (years)  10.5±7.5  
Medications, no (%)    
   Anti-hypertensive agents 58 (95.1) 65 (98.5) 0.273 
      ACEi or ARBs 39 (63.9) 62 (93.9) <0.001 
      Calcium channel blockers 18 (29.5) 14 (21.2) 0.282 
      Diuretics 29 (47.5) 28 (42.4) 0.562 
      Beta-blockers 18 (29.5) 15 (22.7) 0.384 
   Statins 20 (32.8) 52 (78.8) <0.001 
 27 
   Insulin   22 (33.3)  
   Metformin   57 (86.4)  
   Sulfonylureas  22 (33.3)  
Laboratory Parameters    
Fasting glucose (mmol/L)* 5.5 [5.0-6.1] 7.9 [6.5-8.8] <0.001 
Fasting insulin (pmol/L)* 65.0 [44.1-92.9] 55.8 [43.1-87.7] 0.698 
Hemoglobin A1c (%)  7.6 [7.0-8,4]  
HOMA-IR  2.7 [1.7-3.6] 3.2 [2.3-4.6] 0.043 
HDL (mmol/L) 1.3±0.3 1.2±0.3 0.035 
LDL (mmol/L) 3.0±1.0 2.1±0.6 <0.001 
Triglycerides (mmol/L) 1.3 [1.0-2.0] 1.5 [1.1-2.2] 0.326 
Total cholesterol (mmol/L) 5.1±1.2 4.1±0.8 <0.001 
Arterial Stiffness and Hemodynamics (measured supine) 
cfPWV (m/s) 9.2±1.9 10.3±2.7 0.009 
Aortic stiffness β0 15.1 [12.3-19.8] 19.8 [15.0-25.8] 0.003 
crPWV (m/s) 8.6±1.1 8.9±1.3 0.184 
Brachial SBP (mmHg) 131±13 129±15 0.630 
Brachial DBP (mmHg) 82±9 78±9 0.030 
Brachial PP (mmHg) 49±10 51±13 0.284 
Central SBP (mmHg) 121±12 119±14 0.454 
Central DBP (mmHg) 83±9 79±9 0.030 
Central PP (mmHg) 38±10 40±13 0.421 
MAP (mmHg) 99±10 97±10 0.120 
 28 
AIx75 (%) 22.8±10.8 23.2±8.7 0.836 
Pulse Pressure Amplification 1.3±0.2 1.3±0.2 0.991 
Resting HR (beats/minute) 66.1±9.8 68.5±11.1 0.205 
Left ventricular ejection duration (ms) 323.8±26.8 321.0±31.6 0.594 
Blood Pressure (measured seated)    
Brachial SBP (mmHg) 125±12 125±16 0.983 
Brachial DBP (mmHg) 79±9 76±11 0.079 
 541 
Values expressed as mean±standard deviation, median [interquartile range], or number (%) as 542 
appropriate.  543 
*Not measured in participants with T2DM on insulin therapy (n=34).  544 
 545 
ACEi, angiotensin-converting enzyme inhibitor; Aix75, augmentation index corrected for a heart 546 
rate of 75 beats/minute; ARB, angiotensin receptor blocker; cfPWV, carotid-femoral pulse wave 547 
velocity; crPWV, carotid-radial pulse wave velocity; DBP, diastolic blood pressure; HDL, high 548 
density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; HR, heart rate; 549 
LDL, low density lipoprotein; MAP, mean arterial pressure; PP, pulse pressure; SBP, systolic 550 
blood pressure; T2DM, type 2 diabetes mellitus.  551 
 552 
  553 
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Table 2. Between-group differences in arterial stiffness and hemodynamics in initial 554 













14.8 (14.3, 15.3) 15.0 (14.5, 15.5) 0.2 (-0.6, 1.0) 
VO2peak (mL/kg/min) 24.3 (23.1, 25.5) 24.0 (22.9, 25.2) -0.3 (-2.0, 1.5) 
Max HR (beats/min) 154.0 (148.8, 159.2) 153.1 (148.2, 158.0) -0.9 (-8.5, 6.7) 
Peak SBP (mmHg) 173.1 (166.2, 180.0) 182.8 (176.3, 189.4) 9.7 (-0.4, 19.8) 




164.0 (158.6, 169.5) 173.0 (167.8, 178.2) 8.9 (0.9, 16.9) 
Brachial DBP 
(mmHg) 
82.7 (80.7, 84.8) 84.1 (82.1, 86.1) 1.4 (-1.7, 4.5) 
Brachial PP (mmHg) 81.4 (76.886.1) 88.8 (84.4, 93.2) 7.4 (0.6, 14.2) 
cfPWV (m/s) 12.8 (12.0, 13.7) 14.5 (13.7, 15.3) 1.6 (0.4, 2.9) 
Aortic stiffness β0   35.0 (29.7, 40.2) 43.6 (38.7, 48.6) 8.7 (1.0, 16.4) 
HR (beats/min)  98.3 (94.7, 101.8) 98.6 (95.3, 102.0) 0.4 (-4.8, 5.6) 
 30 
5 minutes 
crPWV (m/s)  8.7 (8.3, 9.0) 8.9 (8.6, 9.2) -0.3 (-0.2, 0.7) 
Central SBP 
(mmHg) 
118.2 (115.0, 121.4) 121.1 (118.0, 124.2) 2.9 (-1.7, 7.7) 
Central DBP 
(mmHg) 
79.6 (77.6, 81.6) 81.2 (79.3, 83.1) 1.6 (-1.4, 4.6) 
Central PP (mmHg) 38.6 (36.2, 41.0) 40.0 (37.7, 42.2) 1.36 (-2.1, 5.0) 
AIx75 (%) 26.0 (24.3, 27.7) 24.4 (22.8, 26.0) -1.6 (-4.1, 1.0) 
Ejection duration 
(ms) 
302.6 (296.1, 309.1) 304.8 (298.6, 311.0) 2.2 (-7.3, 11.7) 
 556 
AIx75, augmentation index corrected for a heart rate of 75 beats/minute; cfPWV, carotid-femoral 557 
pulse wave velocity; crPWV, carotid-radial pulse wave velocity; DBP, diastolic blood pressure; 558 
PP, pulse pressure; SBP, systolic blood pressure; VO2peak; peak oxygen consumption.  559 
Adjusted means (95% CI) are presented.  560 
Exercise time, VO2peak, maximal HR, ejection duration, HR and AIx75 are adjusted for age, sex, 561 
waist:hip ratio and ACEi/ARB use.  562 
cfPWV and crPWV are adjusted for the pre-exercise value, age, sex, waist:hip ratio, ACEi/ARB 563 
use, as well as HR and MAP at the time of measurement. 564 
Aortic stiffness β0 and BP is adjusted for for the pre-exercise value, age, sex, waist:hip ratio, 565 
ACEi/ARB use, and HR at the time of measurement.  566 
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Table 3: Between-group differences in the area under the curve for arterial stiffness and 567 
hemodynamics in response to exercise 568 













-6.6 (-64.6, 51.4) 79.9 (25.5, 134.3) 86.5 (2.2, 170.7) 
Brachial DBP 
(mmHgmin) 
-42.7 (-73.7, -11.7) 9.4 (-19.7, 38,4) 52.1 (7.1, 97.1) 
Brachial PP 
(mmHgmin) 
36.2 (-8.4, 80.7) 70.5 (28.7, 112.4) 34.4 (-30.4, 99.2) 
cfPWV (m/smin) 20.7 (12.9, 28.6) 36.3 (28.6, 44.0) 15.5 (4.0, 27.1) 
Aortic stiffness β0  105.3 (66.1, 144.5) 175.6 (137.5, 213.6) 70.2 (12.6, 127.8) 
crPWV (m/smin) -2.3 (-7.7, 3.1) -0.7 (-6.0, 4.7) 1.6 (-6.4, 9.7) 
Central SBP 
(mmHgmin) 
-134.1 (-184.4, -83.9) -79.1 (-126.3, -31.8) 55.1 (-18.4, 128.6) 
Central DBP 
(mmHgmin) 
-33.3 (-64.5, -2.2) 0.7 (-28.6, 30.0) 34.0 (-11.6, 79.6) 
MAP (mmHgmin) -63.3 (-97.6, -28.9) -26.4 (-58.6, 5.9) 36.9 (-13.3, 87.1) 
Central PP 
(mmHgmin) 
-100.8 (-135.7, -65.9) -79.8 (-112.5, -47.0) 21.0 (-30.0, 72.1) 
 32 
AIx75 (%min) -9.0 (-31.3, 13.3) -33.7 (-55.0, -12.3) -24.7 (-57.5, 8.2) 
 569 
All analyses were adjusted for age, sex, waist:hip ratio, and ACEi/ARB use. Adjusted means 570 
(95% CI) are presented.  571 
 572 
AIx75, augmentation index corrected for a heart rate of 75 beats/minute; BP, blood pressure; 573 
cfPWV, carotid-femoral pulse wave velocity; crPWV, carotid-radial pulse wave velocity; HR, 574 
heart rate; MAP, mean arterial pressure; PP, pulse pressure; T2DM, type 2 diabetes mellitus.  575 
